rdf:type |
|
lifeskim:mentions |
umls-concept:C0001617,
umls-concept:C0003360,
umls-concept:C0021149,
umls-concept:C0033045,
umls-concept:C0036525,
umls-concept:C0123931,
umls-concept:C0205195,
umls-concept:C0392756,
umls-concept:C0948715,
umls-concept:C0995188,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C2709058
|
pubmed:issue |
7
|
pubmed:dateCreated |
2010-3-29
|
pubmed:abstractText |
: The multinational MABEL study of 1147 patients with metastatic colorectal cancer (mCRC) who had recently failed an irinotecan-containing regimen confirmed in a community practice setting the efficacy and safety of cetuximab combined with irinotecan.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
AIM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Apr
|
pubmed:issn |
0008-543X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1827-37
|
pubmed:meshHeading |
pubmed-meshheading:20143444-Adrenal Cortex Hormones,
pubmed-meshheading:20143444-Aged,
pubmed-meshheading:20143444-Antibodies, Monoclonal,
pubmed-meshheading:20143444-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20143444-Camptothecin,
pubmed-meshheading:20143444-Colorectal Neoplasms,
pubmed-meshheading:20143444-Disease-Free Survival,
pubmed-meshheading:20143444-Female,
pubmed-meshheading:20143444-Histamine H1 Antagonists,
pubmed-meshheading:20143444-Humans,
pubmed-meshheading:20143444-Hypersensitivity,
pubmed-meshheading:20143444-Infusions, Intravenous,
pubmed-meshheading:20143444-Male,
pubmed-meshheading:20143444-Middle Aged,
pubmed-meshheading:20143444-Neoplasm Metastasis,
pubmed-meshheading:20143444-Premedication,
pubmed-meshheading:20143444-Retreatment
|
pubmed:year |
2010
|
pubmed:articleTitle |
Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication.
|
pubmed:affiliation |
Division of Medical Oncology Falck, Niguarda Ca' Granda Hospital, Milan, Italy. salvatore.siena@ospedaleniguarda.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|